Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Zorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 2/20 | 0.80 |
| ▸ | HSP90AB1 known ✓ | P08238 | 2/20 | 0.80 |
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.78 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.78 |
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 0.78 |
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.78 |
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.78 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.78 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.78 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.78 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.78 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.78 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.78 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.78 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.78 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.78 |
| ▸ | OPRD1 known ✓ | P41143 | 2/20 | 0.78 |
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.78 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.78 |
| ▸ | GHSR known ✓ | Q92847 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zorubicin SCHEMBL4023 | 1.00 | S100A4 (0.83) | S100A4PAX8BRCA1STAT6CYP1A2 | |
| Zorubicin SCHEMBL4024 | 1.00 | S100A4 (0.83) | S100A4PAX8BRCA1STAT6CYP1A2 | |
| Zorubicin SCHEMBL1651187 | 0.99 | S100A4 (0.84) | S100A4PAX8BRCA1STAT6CYP1A2 | |
| Zorubicin SCHEMBL29352324 | 0.99 | S100A4 (0.84) | S100A4PAX8BRCA1STAT6CYP1A2 | |
| Zorubicin SCHEMBL13840951 | 0.99 | S100A4 (0.84) | S100A4PAX8BRCA1STAT6CYP1A2 | |
| Zorubicin SCHEMBL8231 | 0.99 | S100A4 (0.84) | S100A4PAX8BRCA1STAT6CYP1A2 | |
| Zorubicin SCHEMBL8232 | 0.99 | S100A4 (0.84) | S100A4PAX8BRCA1STAT6CYP1A2 | |
| Zorubicin SCHEMBL27835878 | 0.97 | S100A4 (0.81) | S100A4PAX8BRCA1STAT6CYP1A2 | |
| Zorubicin SCHEMBL28142133 | 0.97 | MEN1 (0.82) | S100A4PAX8BRCA1STAT6CYP1A2 | |
| Zorubicin SCHEMBL4759324 | 0.95 | MEN1 (0.79) | S100A4PAX8BRCA1STAT6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| CN-119925621-A | Protective agent of liposome medicine and application thereof | 上海益诺思生物技术股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250100998-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | disclosed |
| US-20250066328-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2025024811-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025024663-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| EP-4469448-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-119013306-A | Antigen binding domains and methods of use thereof | 森迪生物科学公司 | 2024-11-22 | — | — | CN | disclosed |
| US-12071350-B2 | Modified carbon nanomaterial, nanocluster, substance delivery carrier and pharmaceutical composition | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2024-08-27 | — | — | US | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| CN-116407576-A | Pharmaceutical composition and application of preparation thereof in preparation of medicines for treating cancers | 北京同仁堂科技发展股份有限公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-108602849-B | RNA ligand-displaying exosomes for specific delivery of therapeutic agents to cells by RNA nanotechnology | 俄亥俄州国家创新基金会 | 2022-10-21 | — | — | CN | disclosed |
| CN-114957291-A | Bivalent bromodomain inhibitors and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20220169517-A1 | MODIFIED CARBON NANOMATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER AND PHARMACEUTICAL COMPOSITION | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2022-06-02 | — | — | US | disclosed |
| US-20220133914-A1 | OPTICALLY HEAT-GENERATING COMPOSITE MATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER AND PHARMACEUTICAL COMPOSITION | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133914-A1 | OPTICALLY HEAT-GENERATING COMPOSITE MATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER AND PHARMACEUTICAL COMPOSITION | CHRM1, NPY1R, C1R | HSP90AA1 154/4885HSP90AB1 168/4885TOP2A 4488/4885 |
| US-20250066328-A1 | PARP7 INHIBITORS | PARP1, PARP2, PARP8 | HSP90AA1 2848/4885HSP90AB1 2303/4885TOP2A 90/4885 |
| US-20250100998-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | HSP90AA1 3074/4885HSP90AB1 2597/4885TOP2A 103/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | HSP90AA1 3074/4885HSP90AB1 2597/4885TOP2A 103/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | HSP90AA1 3074/4885HSP90AB1 2597/4885TOP2A 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.